Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Evatanepag. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER2 known ✓ | P43116 | 12/20 | 1.00 |
| ▸ | CA12 | O43570 | 6/20 | 0.77 |
| ▸ | CA1 | P00915 | 6/20 | 0.77 |
| ▸ | CA2 | P00918 | 6/20 | 0.77 |
| ▸ | CA4 | P22748 | 6/20 | 0.77 |
| ▸ | CA9 | Q16790 | 6/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Evatanepag SCHEMBL29376960 | 1.00 | PTGER2 (1.00) | PTGER2CA12CA1CA2CA4 | |
| Evatanepag SCHEMBL1147493 | 1.00 | PTGER2 (1.00) | PTGER2CA12CA1CA2CA4 | |
| Evatanepag SCHEMBL1147496 | 0.99 | PTGER2 (0.98) | PTGER2CA12CA1CA2CA4 | |
| Evatanepag SCHEMBL1147494 | 0.99 | PTGER2 (0.98) | PTGER2CA12CA1CA2CA4 | |
| Evatanepag SCHEMBL1147489 | 0.99 | PTGER2 (0.98) | PTGER2CA12CA1CA2CA4 | |
| SCHEMBL6284518 | 0.94 | PTGER2 (0.88) | PTGER2CA12CA1CA2CA4 | |
| SCHEMBL6278874 | 0.93 | PTGER2 (0.87) | PTGER2CA12CA1CA2CA4 | |
| SCHEMBL13407391 | 0.93 | PTGER2 (0.86) | PTGER2CA12CA1CA2CA4 | |
| SCHEMBL6276293 | 0.92 | PTGER2 (0.85) | PTGER2CA12CA1CA2CA4 | |
| SCHEMBL6283458 | 0.92 | PTGER2 (0.85) | PTGER2CA12CA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210113651-A1 | ANTIMICROBIAL ARTICLES PRODUCED BY ADDITIVE MANUFACTURING | ORTHOPAEDIC INNOVATION CENTRE INC (US) | 2021-04-22 | — | — | US | claimed |
| EP-3122393-B1 | SELECTIVE LASER SINTERING PROCESS (SLS) FOR PRODUCING ANTIBIOTIC-ELUTING MEDICAL IMPLANTS | ORTHOPAEDIC INNOVATION CENTRE INC (CA) | 2020-04-22 | — | — | EP | claimed |
| US-20200061239-A1 | ANTIMICROBIAL ARTICLES PRODUCED BY ADDITIVE MANUFACTURING | ORTHOPAEDIC INNOVATION CENTRE INC (CA) | 2020-02-27 | — | — | US | claimed |
| US-10406263-B2 | Antimicrobial articles produced by additive manufacturing | ORTHOPAEDIC INNOVATION CENTRE INC. (CA) | 2019-09-10 | — | — | US | claimed |
| EP-2919823-B1 | ANTIMICROBIAL ARTICLES PRODUCED BY ADDITIVE MANUFACTURING | ORTHOPAEDIC INNOVATION CENTRE INC (CA) | 2019-07-03 | — | — | EP | claimed |
| US-20170095596-A1 | ANTIMICROBIAL ARTICLES PRODUCED BY ADDITIVE MANUFACTURING | ORTHOPAEDIC INNOVATION CENTRE (CA) | 2017-04-06 | — | — | US | claimed |
| EP-3122393-A1 | ANTIMICROBIAL ARTICLES PRODUCED BY ADDITIVE MANUFACTURING | Orthopaedic Innovation Centre Inc. (CA) | 2017-02-01 | — | — | EP | claimed |
| US-20150290280-A1 | ANTIMICROBIAL ARTICLES PRODUCED BY ADDITIVE MANUFACTURING | ORTHOPAEDIC INNOVATION CENTRE INC. (US) | 2015-10-15 | — | — | US | claimed |
| WO-2015143553-A1 | ANTIMICROBIAL ARTICLES PRODUCED BY ADDITIVE MANUFACTURING | ORTHOPAEDIC INNOVATION CENTRE INC. (CA) | 2015-10-01 | — | — | WO | claimed |
| EP-2919823-A1 | ANTIMICROBIAL ARTICLES PRODUCED BY ADDITIVE MANUFACTURING | Orthopaedic Innovation Centre Inc. (CA) | 2015-09-23 | — | — | EP | claimed |
| US-20030166631-A1 | Pharmaceutical compositions and methods for administering EP2 receptor selective agonists | DUMONT FRANCIS (US) | 2003-09-04 | — | — | US | claimed |
| US-20030104031-A1 | Controlled release polymeric compositions of bone growth promoting compounds | DUMONT FRANCIS (US) | 2003-06-05 | — | — | US | claimed |
| WO-2003045351-A1 | CONTROLLED RELEASE POLYMERIC COMPOSITIONS OF BONE GROWTH PROMOTING COMPOUNDS | PFIZER INC. (US) | 2003-06-05 | — | — | WO | claimed |
| WO-2003045371-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR ADMINISTERING EP2 RECEPTOR SELECTIVE AGONISTS | PFIZER PRODUCTS INC. (US) | 2003-06-05 | — | — | WO | claimed |
| US-20030078261-A1 | Prostaglandin agonists | CAMERON KIMBERLY O (US) | 2003-04-24 | — | — | US | claimed |
| US-6498172-B1 | (3-(((4-TERT-BUTYL-BENZYL)-(PYRIDINE-3-SULFONYL)-AMINO)-METHYL) -PHENOXY)-ACETIC ACID OR SALT; TREATING SUCH AS OSTEOPOROSIS | PFIZER INC. | 2002-12-24 | — | — | US | claimed |
| US-20020161026-A1 | Combination therapies for the stimulation of bone growth | PARALKAR VISHWAS M (US) | 2002-10-31 | — | — | US | claimed |
| US-20020115695-A1 | Combination therapies for the stimulation of bone growth | PARALKAR VISHWAS M (US) | 2002-08-22 | — | — | US | claimed |
| EP-1205189-A2 | Combination of a prostaglandin agonist and a HMG-CoA reductase inhibitor for the stimulation of bone growth | Pfizer Products Inc. (US) | 2002-05-15 | — | — | EP | claimed |
| EP-1108426-A2 | Use of prostaglandin agonists to treat erectile dysfunction or impotence | Pfizer Products Inc. (US) | 2001-06-20 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078261-A1 | Prostaglandin agonists | PTGER1, PTGER4, PTGIR | PTGER2 4/4885CA12 4780/4885CA1 4650/4885 |
| US-20030166631-A1 | Pharmaceutical compositions and methods for administering EP2 receptor selective agonists | PTGER2, PTGER1, PTGFR | PTGER2 1/4885CA12 3614/4885CA1 4380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.